A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Category Primary study
JournalEUROPEAN HEART JOURNAL
Year 2024
This article has no abstract
Epistemonikos ID: a900e384169ce0dbde9caf249e6ec9b5acfaafd9
First added on: Jan 24, 2025